One man’s frankenfood is another man’s solution to world hunger. Intrexon is developing technology that uses synthetic biology, or biological engineering, to make advances in everything from pharmaceuticals to genetically modified plants and animals. The company has development agreements with AmpliPhi (antibacterial medication), AquaBounty (genetically modified salmon), BioLife (genetic disease), Eli Lilly (animal medication), Fibrocell (dermatology medication), Genopaver (pharmaceutical ingredients), Oragenics (antibiotics), Soligenix (antibiotics), Synthetic Biologics (antibiotics), and ZIOPHARM (cancer medicine). Intrexon went public in 2013, raising $160 million in its IPO.